A Call to Lead @LifeScience ORG

LifeScience ORG
  • 0.0 (0)
  • EMPRENDIMIENTO

A Call To Lead is a series shining a light on the leadership, vision, and impact of European life science CEOs who are proving that world-class ventures don’t need to be built in Boston to shape the future of healthcare. Each episode features a one-on-one conversation with a European life science CEO and member of the LifeScience ORG community. Our conversations are not about companies or pipelines; instead, guests reflect on their personal journeys, the pivotal choices that shaped their careers, and the future they are helping to build. These kinds of insights are rarely shared publicly. New episodes are released every Thursday.

  1. Camilla Easter, Oxford Medical Products

    HACE 2 DÍAS

    Camilla Easter, Oxford Medical Products

    Why lead a company into the increasingly crowded obesity space? How do you go from a career in veterinary surgery to CEO of a medtech company? And what is so magical about Oxford when it comes to life science? Today I’m joined by Camilla Easter, CEO of Oxford Medical Products (OMP), a late-stage medtech company based in Witney, Oxfordshire, in the UK. OMP’s lead product is a non-pharmacological treatment for obesity in overweight patients. We’ll talk more about the science at the end of the episode, but first Camilla shares her journey to leadership from the vet clinic. About LifeScience ORG It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare. The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms. Timestamps Introduction (0:00)From Veterinary Surgery to Biotech Leadership (0:53)The Call to Lead: Finding Your Path (1:50)Career Transitions: Navigating Change (4:30)Stepping Into CEO Role (7:55)Personal Challenges and Defining Moments (10:49)Shared Challenges in Life Science Leadership (15:42)Leadership Lessons: Communication & Community (17:47)The European Life Science Ecosystem (20:39)Tackling the Obesity Crisis: Why This Problem? (21:47)The Technology: A Non-Pharmacological Solution (25:21)Ecosystem Solutions: What We Can Do Together (27:13)A Vision for the Future (33:09)Final Thoughts: Embracing Failure and Learning (35:49)

    38 min
  2. Victor Bustos, Refoxy Pharma

    19 FEB

    Victor Bustos, Refoxy Pharma

    Why does the perception of facts matter when talking to investors? How do you attract a US-based chair to a European company’s board? And what are the advantages of running a virtual biotech with no labs of its own? Today, I’m joined by Victor Bustos, CEO of Refoxy Pharma. Refoxy is a "virtual biotech" located in Cologne, Germany, and is developing small-molecule drugs for the treatment of age-related disease. About LifeScience ORG It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare. The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms. Timestamps: 0:00 - Introduction: The Leadership Journey 1:24 - From Academia to Entrepreneurship 6:00 - Early Leadership Challenges: Truth vs. Perception 7:24 - Communication Skills & Stakeholder Management 10:37 - Peer Learning & Strategic Thinking 12:05 - Building Your Board: Attracting US Talent to Europe 13:29 - Virtual Biotech Model: Advantages & Strategy 16:26 - Due Diligence in CRO Partnerships 18:09 - The Science: Targeting Age-Related Disease 20:01 - Strategic Indication Selection: IPF Case Study 22:01 - Ecosystem Collaboration & Regulatory Landscape 23:31 - The Future of Longevity Medicine 25:25 - Leadership Philosophy: Leading by Example

    29 min
  3. Mark Gaffney, Calluna Pharma

    12 FEB

    Mark Gaffney, Calluna Pharma

    How does a United States Air Force officer end up leading a European biotech company? Is there an advantage to leading a company that’s based half a world away? And are you doing a regrets analysis as part of your decision-making? This week I’m joined by Mark Gaffney, a Boston-based CEO leading Calluna Pharma. Calluna is a Norwegian company developing therapeutics for inflammatory and fibrotic diseases, such as IPF – but we’ll get into the science later in the episode. First, Mark shares his story on what drew him into life science and how he got from the US air force and into C-suite. About LifeScience ORG It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare. The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms. Timestamps 1:30 - From Military Service to Biotech Leadership 1:45 - Personal Motivation: Fighting Retinitis Pigmentosa 3:10 - Career Transition: Law to Life Sciences 5:36 - Stepping Up to CEO: Overcoming Imposter Syndrome 7:49 - Leadership Lessons from the Air Force 12:00 - Leading Across Continents: Virtual Leadership Strategies 16:14 - The Regrets Analysis: A Decision-Making Framework 20:03 - European Biotech Innovation and Efficiency 22:13 - Calluna Pharma: Tackling IPF with Novel Targets 24:02 - Navigating Risk in Novel Target Development 25:35 - Ecosystem Support for Inflammatory Disease Research 28:32 - Building and Empowering High-Performance Teams

    32 min
  4. Maximilien Levesque, AQEMIA

    5 FEB

    Maximilien Levesque, AQEMIA

    What inspires a theoretical physicist to start a drug invention company? How do you choose the right co-founder when you're coming from academia? And, in a multi-site, multi-cultural European organisation – how does a leader manage communication with the team? I’m joined by Maximilien Levesque, physics academic turned entrepreneur, CEO and co-founder of Paris and London-based company AQEMIA. Aqemia uses a mix of physics and generative AI to invent therapeutics for poorly treated diseases. More on the science towards the end of the episode, but first Max explains what inspired him to found AQEMIA and how he's faced challenges from selecting a co-founder to communicating and maintaining team alignment as his company grows in two locations. About LifeScience ORG It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare. The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms. Timestamps 00:00 Introduction and Host Welcome 00:27 Max's Story 05:08 Challenges and Realizations in the Leadership Journey 07:09 Finding the Right Co-Founder 10:32 Building a Multicultural, Multidisciplinary Company 13:44 Maintaining Team Alignment 14:50 European Life Science Landscape 17:09 Generative AI in Drug Discovery 24:42 Vision for the Future 26:23 Leadership Insights

    29 min
  5. Jack O'Meara, Aerska

    20/11/2025

    Jack O'Meara, Aerska

    This isn't Jack O'Meara's first rodeo. As CEO of Ochre Bio, he saw the company bring in millions to develop pioneering RNA therapies for liver disease. With his new venture Aerska, he's looking at bringing the transformative potential of targeted RNA therapy to the realm of neurological disease. In this episode of A Call to Lead, David Kirk speaks with Jack O’Meara, CEO and co-founder of Aerska, about his personal story behind tackling neurodegenerative disease and the realities of leading biotech companies in Europe. Jack shares candid lessons on decision-making, context-driven leadership, and building transatlantic networks to scale innovation.

    31 min
  6. Avencia Sánchez-Mejías, Integra Therapeutics

    13/11/2025

    Avencia Sánchez-Mejías, Integra Therapeutics

    Biotech leader Avencia Sánchez-Mejías, CEO of Integra Therapeutics, joins A Call to Lead to share her leadership and entrepreneurship story, as well as her take on innovation in Europe’s fast-rising life sciences ecosystem. In this episode of A Call To Lead, Avencia shares lessons on resilience, uncertainty, diversity, and the human side of leadership in science-driven entrepreneurship. Listen to her journey from academia to biotech CEO, her vision for safer gene editing, and how resilient leadership is reshaping European biotechnology.

    32 min
  7. Samir Ounzain, HAYA Therapeutics

    06/11/2025

    Samir Ounzain, HAYA Therapeutics

    How do you lead a company across continents and through uncertainty? In this episode of A Call to Lead, David Kirk speaks with Samir Ounzain, CEO and scientific co-founder of Haya Therapeutics. Samir shares how a lifelong curiosity about how cells “speak” to their environment led him from academia to building a company at the frontier of RNA-guided medicine. He reflects on what it takes to lead through uncertainty, translate visionary science into tangible therapies, and build culture and alignment across continents. This conversation is a masterclass in marrying deep biology with purposeful leadership.

    37 min
  8. Alexandre Le Vert, Osivax

    30/10/2025

    Alexandre Le Vert, Osivax

    The birth of Alexandre Le Vert's daughter amidst a global 'flu scare put him on the path to leadership. Now, he's the co-founder and executive Chair of Osivax, a clinical-stage biotech company focusing on vaccine research and development based in Lyon, France.  In this episode of A Call To Lead, Alex shares his series of fortunate events that led him to co-found Osivax, challenges he faced getting to grips with the legal obligations of leadership, and the lessons he learned from great mentors along the way.

    34 min
Ver todo (13)

Tráiler

Acerca de

A Call To Lead is a series shining a light on the leadership, vision, and impact of European life science CEOs who are proving that world-class ventures don’t need to be built in Boston to shape the future of healthcare. Each episode features a one-on-one conversation with a European life science CEO and member of the LifeScience ORG community. Our conversations are not about companies or pipelines; instead, guests reflect on their personal journeys, the pivotal choices that shaped their careers, and the future they are helping to build. These kinds of insights are rarely shared publicly. New episodes are released every Thursday.

Información

  • Creador
    LifeScience ORG
  • Años de actividad
    2025 - 2026
  • Episodios
    13
  • Clasificación
    Apto
  • Copyright
    © Copyright LifeScience Connect Ltd
  • Mostrar sitio web
    A Call to Lead @LifeScience ORG